Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT 4:00:00 PM EDT
Products, Regulatory
Arcturus Therapeutics Announces Clinical Trial Application For Arct-032 Received Approval
Published: 01/31/2023 13:38 GMT
Arcturus Therapeutics Holdings Inc (ARCT) - Arcturus Therapeutics Announces Clinical Trial Application for Arct-032 Received Approval to Proceed Into First-in-human Studies to Treat Cystic Fibrosis.
Arcturus Therapeutics Announces Clinical Trial Application for Arct-032 Received Approval to Proceed Into First-in-human Studies to Treat Cystic Fibrosis.
Arcturus Therapeutics Holdings - Clinical Trial Application for Arct-032 Received Approval to Proceed Into Phase 1 First-in-human Study in New Zealand.
Arcturus Therapeutics Announces Clinical Trial Application for Arct-032 Received Approval to Proceed Into First-in-human Studies to Treat Cystic Fibrosis.
Arcturus Therapeutics Holdings - Clinical Trial Application for Arct-032 Received Approval to Proceed Into Phase 1 First-in-human Study in New Zealand.